Results 191 to 200 of about 42,587 (212)
Some of the next articles are maybe not open access.
A Giant Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: Case Report
Clinical Laboratory, 2023Anaplastic lymphoma kinase-positive (ALK+) large cell lymphoma (ALCL) is a systemic lymphoma. The invasion of the head and neck bone and skin by ALK+ ALCL is relatively uncommon in children.We describe a 13-year-old boy diagnosed with ALK+ ALCL.He went a surgery of sampling biopsy procedure.
Xi, Dai +6 more
openaire +2 more sources
Molecular Biology of Anaplastic Lymphoma Kinase–Positive Anaplastic Large-Cell Lymphoma
Journal of Clinical Oncology, 2002ABSTRACT: Anaplastic large-cell lymphoma (ALCL) provides an excellent example of how molecular insights into tumor pathogenesis are influencing and improving tumor classification. ALCL was described initially as a subtype of T-cell/null-cell lymphoma characterized by unusual tumor cell morphology and the expression of CD30.
Jeffery L, Kutok, Jon C, Aster
openaire +2 more sources
Anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma
Egyptian Journal of Dermatology and VenereologyAnaplastic large-cell lymphoma (ALCL) is a non-Hodgkin T-cell lymphoma characterized by persistent expression of CD 30 antigen that represents 2–3% of non-Hodgkin lymphoma (NHL). ALCL may present as a primary cutaneous disease or systemic disease with secondary cutaneous involvement. World Health Organization (WHO) classifies ALCL into ALK-positive and
Shraddha Kote +3 more
openaire +1 more source
Anaplastic Lymphoma Kinase in Human Cancer
Critical Reviews™ in Oncogenesis, 2012The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. This review will discuss our current understanding of ALK in human cancer and the implication of recent results for ...
Christina, Schonherr +2 more
openaire +2 more sources
Anaplastic lymphoma kinase proteins and malignancy
Current Opinion in Hematology, 2001The anaplastic lymphoma kinase (ALK) gene fuses to the nucleophosmin (NPM) gene as a result of a (2;5) translocation associated with a subtype of human lymphoma (initially designated anaplastic large cell lymphoma [ALCL] or Ki-1/CD30-positive lymphoma).
K, Pulford, S W, Morris, D Y, Mason
openaire +2 more sources
FDG PET/CT in Anaplastic Lymphoma Kinase–Positive Anaplastic Large Cell Lymphoma
Clinical Nuclear Medicine, 2020Abstract Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin’s lymphoma, with rearrangements of the anaplastic lymphoma kinase gene in 60%–85% of systemic cases. We report an 11-year-old boy with ALCL in whom serial FDG PET/CT revealed partial response and complete metabolic response at interim and end of treatment, respectively ...
Meivel, Angamuthu +5 more
openaire +2 more sources
Crizotinib: An Anaplastic Lymphoma Kinase Inhibitor
Future Oncology, 2011Crizotinib is an oral small-molecule inhibitor of ALK and c-Met tyrosine kinases that is being developed by Pfizer. ALK mutations or gene rearrangements result in growth factor-independent ALK activation. Most of the available clinical data with crizotinib are in patients with tumors that have an activated ALK, and the drug has shown very promising ...
Shirish M, Gadgeel, Gerold, Bepler
openaire +2 more sources
The anaplastic lymphoma kinase testing conundrum
Expert Review of Molecular Diagnostics, 2015Given the excellent results of the clinical trials with anaplastic lymphoma kinase (ALK) inhibitors, the importance of accurately identifying ALK-positive lung carcinoma patients has never been greater. It brings with it a pressing need for harmonized development of companion diagnostics, for economic, scientific and medical reasons.
Esther, Conde +2 more
openaire +2 more sources
Cancer Research, 2008
Abstract Selective kinase inhibitors have had a substantial impact on the field of medical oncology. Whereas these agents can elicit dramatic clinical responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.
Ultan, McDermott +15 more
openaire +2 more sources
Abstract Selective kinase inhibitors have had a substantial impact on the field of medical oncology. Whereas these agents can elicit dramatic clinical responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.
Ultan, McDermott +15 more
openaire +2 more sources
Human Pathology, 2011
Retroperitoneal fibrosis is a rare fibroinflammatory condition involving the abdominal aorta, iliac vessels, and ureters that carries an association with several other autoimmune conditions. Most cases of retroperitoneal fibrosis are thought to be idiopathic.
Suntrea T G, Hammer +2 more
openaire +2 more sources
Retroperitoneal fibrosis is a rare fibroinflammatory condition involving the abdominal aorta, iliac vessels, and ureters that carries an association with several other autoimmune conditions. Most cases of retroperitoneal fibrosis are thought to be idiopathic.
Suntrea T G, Hammer +2 more
openaire +2 more sources